S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer
NCT00792701
Completed
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy drugs after surgery may kill any tumor cells that remain after surgery. Sometimes, after surgery, the tumor may not need more treatment until it progresses. In this case, observation may be sufficient. PURPOSE: This phase II trial is studying how well giving gemcitabine together with... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
02/19/2020
Locations: Hembree Mercy Cancer Center at St. Edward Mercy Medical Center, Fort Smith, Arkansas +146 locations
Conditions: Lung Cancer
Register for Updates
Neoadjuvant Paclitaxel Poliglumex, Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial (CTI#X64001)
NCT00522795
Completed
Neoadjuvant Paclitaxel Poliglumex (PPX; CT-2103), Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial. (CTI#X64001
Gender:
ALL
Ages:
19 years and above
Trial Updated:
02/13/2020
Locations: Lifespan Hospitals, Providence, Rhode Island
Conditions: Esophageal Cancer
Register for Updates
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
NCT00613626
Completed
At this point in the treatment of extensive stage SCLC, we have reached a plateau in survival with conventional chemotherapy and newer regimens are greatly needed. It has been noted that patients with increased VEGF levels have a poorer prognosis. Anti-angiogenic agents hold significant promise in the treatment of patients with extensive stage SCLC. ZD6474, a new inhibitor of the VEGFR-2, has shown favorable action in NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/07/2020
Locations: Helen F. Graham Cancer Center, Newark, Delaware +18 locations
Conditions: Small Cell Lung Cancer
Register for Updates
Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases
NCT01114958
Completed
This phase I study proposes the use of systemic thiosulfate rescue to allow supradose intra-arterial cisplatin delivery to lung tumors. Eligible patients would be those with at least one lung lesion large enough of characterize angiographically. All patients will first undergo a CT arteriogram of the target tumor. Patients will then receive 2 treatments on 2 consecutive weeks. The primary endpoint will be toxicity, with secondary endpoint of response as measured on week 4. This pilot study will... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2020
Locations: University of California, San Diego Moores Cancer Center, La Jolla, California
Conditions: Lung Neoplasms, Neoplasm Metastasis
Register for Updates
Pilot Study of Hyperthermic Peritoneal Perfusion (HIPEC) for Adolescent and Young Adults With Desmoplastic Small Round Cell Tumor
NCT01277744
Completed
The goal of this clinical research study is to learn if heated intra-abdominal cisplatin can help to control abdominal tumors in patients having surgery to remove the tumors. The safety of this drug will also be studied.
Gender:
ALL
Ages:
1 year and above
Trial Updated:
01/08/2020
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Cancers, Sarcoma
Register for Updates
Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies
NCT02620839
Terminated
This phase Ib trial studies the best dose and side effects of alpelisib and cisplatin in treating patients with human papillomavirus (HPV) positive solid tumor malignancies. Alpelisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving alpelisib and ci... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/07/2020
Locations: UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California
Conditions: Solid Tumors
Register for Updates
Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer
NCT02726399
Terminated
The purpose of this study is to compare any good and bad effects of using ramucirumab along with the usual trastuzumab and chemotherapy to using the usual chemotherapy and trastuzumab alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/06/2020
Locations: Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey +5 locations
Conditions: Gastric Cancer, Gastroesophageal Junction Cancer
Register for Updates
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer
NCT01445405
Completed
Background: Bortezomib acts on molecules in head and neck cancer cells that are important for the cells growth and survival. The drug may help make the cancer more sensitive to radiation and other chemotherapy drugs. Cetuximab is a monoclonal antibody that has increased the effectiveness of radiation treatment in patients with head and neck cancer in clinical trials. Cisplatin has shrunk head and neck cancers and improved treatment response and survival when combined with radiation treatment.... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
12/14/2019
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: Carcinoma, Squamous, Head and Neck Cancer, Oral Cancer, Laryngeal Cancer, Pharyngeal Cancer
Register for Updates
A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic Cholangiocarcinoma
NCT02994251
Terminated
The study will be a single-center, single-arm, Phase II study of gemcitabine and cisplatin in combination with conventional trans-arterial chemoembolization therapy in adult patients with advanced ICC. 25 patients will be enrolled over the course of 2 years, with an additional 1.5 years for patient follow-up.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2019
Locations: Smilow Cancer Center, New Haven, Connecticut
Conditions: Unresectable Intrahepatic Cholangiocarcinoma
Register for Updates
Soy Isoflavone in Combination With Radiation Therapy and Cisplatin in SCC of the Head and Neck
NCT02075112
Completed
The purpose of this study is to determine if soy supplementation during chemotherapy and radiation therapy will decrease side effects caused by treatment. Long-lasting dry mouth is a side effect of the standard treatment, and we are testing whether soy supplementation during treatment may reduce this symptom and other side effects of chemoradiation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2019
Locations: Emory University Hospital Midtown, Atlanta, Georgia +1 locations
Conditions: Cancer of Head and Neck
Register for Updates
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
NCT00515411
Completed
Chemotherapy given together is a standard way to treat your cancer. One standard treatment includes a combination of docetaxel, cisplatin, and fluorouracil. However, the original combination of these three drugs can cause many side effects. This study is being done to find out if these three drugs can be given at lower doses more often, with fewer side effects and still maintain the same benefit as the standard way of giving this three drug combination. If your tumor overexpresses a protein call... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/25/2019
Locations: City of Hope Cancer Center, Duarte, California +14 locations
Conditions: Gastroesophageal Junction Adenocarcinoma, Gastric Cancer
Register for Updates
Adjuvant Cisplatin and Docetaxel in Non Small Cell Lung Cancer
NCT00582634
Completed
* To determine if docetaxel and cisplatin can be administered in a dose intense manner in the adjuvant setting in resected non-small cell lung cancer * To evaluate the time to progression and overall survival * To evaluate toxicities of this chemotherapy combination in the adjuvant setting * To correlate XPD and ERCC1 polymorphisms with time to progression and toxicities in patients treated with this regimen
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/15/2019
Locations: University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin
Conditions: Non Small Cell Lung Cancer
Register for Updates